Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in hematology and oncology, today
announced key presentations of clinical and scientific data related
to its products at the 56th Annual Meeting of the American Society
of Hematology (ASH), being held in San Francisco, California, from
December 6-9, 2014.
For more information about the ASH annual meeting and for a
complete list of abstracts, please refer to the conference website
at https://ash.confex.com/ash/2014/webprogram/start.html.
The following are key abstracts being presented at the ASH
meeting:
ZEVALIN® (ibritumomab tiuxetan)
Injection-related Abstracts
Abstract #
Type Title
First Author
Date/Time Location
1762 Poster Phase
II study of Yttrium-90 Ibritumomab Tiuxetan (Zevalin) in Patients
with Previously Untreated Marginal Zone Lymphoma
Fabregas
Saturday, Dec 6,
5:30 PM-7:30 PM
West Building, Level 1
(Moscone Center)
1746 Poster
Consolidative Radioimmunotherapy after Chemoimmunotherapy in
Patients with Histologic Transformation of Indolent Lymphoma
Reagan
Saturday, Dec 6,
5:30 PM-7:30 PM
West Building, Level 1
(Moscone Center)
1733 Poster Short
Course of Bendamustine and Rituximab followed by Yttrium-90
Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular
Lymphoma: Results of Fol-BRITe Lansigan
Saturday, Dec 6,
5:30 PM-7:30 PM
West Building, Level 1
(Moscone Center)
3986 Poster
Minimum Tolerable Interval of Radioimmunotherapy and Autologous
Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed
or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides
Excellent Disease Control Hasenkamp
Monday, Dec 8,
6:00 PM-8:00 PM
North Building, Hall E
(Moscone Center)
4455 Poster
Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin Lymphoma: Results
after a Median Follow-up of 5 Years in a Single Institution
Anastasia Monday, Dec 8,
6:00 PM-8:00 PM
West Building, Level 1
(Moscone Center)
4414 Poster Long
term follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation
after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited
Stage Aggressive B-Cell Lymphoma Persky
Monday, Dec 8,
6:00 PM-8:00 PM
West Building, Level 1
(Moscone Center)
Beleodaq® (belinostat) for Injection-related
Abstracts Abstract # Type
Title First
Author Location 3075
Poster Safe and Effective
Treatment of Patients with Relapsed or Refractory Peripheral T-Cell
Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat
Savage Sunday, Dec. 7,
6:00 PM-8:00 PM
West Building, Level 1
(Moscone Center)
265 Oral Big Data
Approach to Identify Molecular Basis for Drug Sensitivity
Phenotypes in Acute Myeloid Leukemia Su-In Lee
Monday, Dec. 8,
7:00 AM-8:30 AM
South Building, Esplanade 301 (Moscone
Center)
N/A Publication
Subsequent Hematopoietic Stem Cell Transplantation in
Belinostat-treated Patients with Relapsed/Refractory Peripheral
T-cell Lymphoma (R/R PTCL) Shustov
Publication only
PTCL-related Abstracts
Abstract # Type
Title First Author
Location
4434
Poster COMPLETE Registry-
Patient Characteristics and Treatment Patterns in United States for
the Most Common Subtypes of Peripheral T-Cell Lymphoma
Pinter-Brown Monday, Dec. 8,
6:00 PM-8:00 PM
West Building, Level 1
(Moscone Center)
Marqibo® (vinCRIStine sulfate LIPOSOME
injection)-related Abstracts Abstract #
Type
Title First
Author Location 4420
Poster
Liposomal Formulation of Vincristine Allows
for Doubling the Dose Compared to Conventional Vincristine: Results
of the First Futility Analysis of the OPTIMAL>60 Study of the
German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Duecker Monday, Dec. 8,
6:00 PM-8:00 PM
West Building, Level 1
(Moscone Center)
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in oncology and hematology. Spectrum
and its affiliates market five oncology drugs: FUSILEV®
(levoleucovorin) for Injection; FOLOTYN® (pralatrexate
injection); ZEVALIN® (ibritumomab tiuxetan) Injection for
intravenous use; MARQIBO® (vinCRIStine sulfate LIPOSOME
injection) for intravenous infusion; and BELEODAQ®
(belinostat) for Injection. Spectrum's strong track record in
in-licensing and acquiring differentiated drugs, and expertise in
clinical development have generated a robust, diversified and
growing pipeline of product candidates in advanced-stage Phase 2
and Phase 3 studies. More information on Spectrum is available at
www.sppirx.com.
About ZEVALIN and the ZEVALIN Therapeutic Regimen
ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is
indicated for the treatment of patients with relapsed or
refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma
(NHL). ZEVALIN is also indicated for the treatment of patients with
previously untreated follicular non-Hodgkin's Lymphoma who achieve
a partial or complete response to first-line chemotherapy.
ZEVALIN is a CD20-directed radiotherapeutic antibody. The
ZEVALIN therapeutic regimen consists of two components: rituximab,
and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN
builds on the combined effect of a targeted biologic monoclonal
antibody augmented with the therapeutic effects of a beta-emitting
radioisotope.
Important ZEVALIN Safety Information
Deaths have occurred within 24 hours of rituximab infusion, an
essential component of the ZEVALIN therapeutic regimen. These
fatalities were associated with hypoxia, pulmonary infiltrates,
acute respiratory distress syndrome, myocardial infarction,
ventricular fibrillation, or cardiogenic shock. Most (80%)
fatalities occurred with the first rituximab infusion. ZEVALIN
administration can result in severe and prolonged cytopenias in
most patients. Severe cutaneous and mucocutaneous reactions, some
fatal, can occur with the ZEVALIN therapeutic regimen.
Please see full Prescribing Information, including BOXED
WARNINGS, for ZEVALIN and rituximab. Full prescribing information
for ZEVALIN can be found at www.ZEVALIN.com.
About BELEODAQ®
Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs
catalyze the removal of acetyl groups from the lysine residues of
histones and some non-histone proteins. In vitro, belinostat caused
the accumulation of acetylated histones and other proteins,
inducing cell cycle arrest and/or apoptosis of some transformed
cells. Belinostat shows preferential cytotoxicity towards tumor
cells compared to normal cells. Belinostat inhibited the enzymatic
activity of histone deacetylases at nanomolar concentrations
(<250 nM).
Please see Beleodaq Full Prescribing Information at
www.beleodaq.com.
Indications and Usage
Beleodaq is a histone deacetylase inhibitor indicated for the
treatment of patients with relapsed or refractory peripheral T-cell
lymphoma (PTCL). This indication is approved under accelerated
approval based on tumor response rate and duration of response. An
improvement in survival or disease-related symptoms has not been
established. Continued approval for this indication may be
contingent upon verification and description of clinical benefit in
the confirmatory trial.
Important Beleodaq Safety Information
Warnings and Precautions
- Beleodaq can cause thrombocytopenia,
leukopenia (neutropenia and lymphopenia), and/or anemia; monitor
blood counts weekly during treatment, and modify dosage as
necessary.
- Serious and sometimes fatal infections,
including pneumonia and sepsis, have occurred with Beleodaq. Do not
administer Beleodaq to patients with an active infection. Patients
with a history of extensive or intensive chemotherapy may be at
higher risk of life threatening infections.
- Beleodaq can cause fatal hepatotoxicity
and liver function test abnormalities. Monitor liver function tests
before treatment and before the start of each cycle. Interrupt or
adjust dosage until recovery, or permanently discontinue Beleodaq
based on the severity of the hepatic toxicity.
- Tumor lysis syndrome has occurred in
Beleodaq-treated patients in the clinical trial of patients with
relapsed or refractory PTCL. Monitor patients with advanced stage
disease and/or high tumor burden and take appropriate
precautions.
- Nausea, vomiting and diarrhea occur
with Beleodaq and may require the use of antiemetic and
antidiarrheal medications.
- Beleodaq can cause fetal harm when
administered to a pregnant woman. Women of childbearing potential
should be advised to avoid pregnancy while receiving Beleodaq. If
this drug is used during pregnancy, or if the patient becomes
pregnant while taking this drug, the patient should be apprised of
potential hazard to the fetus.
Adverse Reactions
- The most common adverse reactions
observed in the trial in patients with relapsed or refractory PTCL
treated with Beleodaq were nausea (42%), fatigue (37%), pyrexia
(35%), anemia (32%), and vomiting (29%).
- Sixty-one patients (47.3%) experienced
serious adverse reactions while taking Beleodaq or within 30 days
after their last dose of Beleodaq.
Drug Interactions
- Beleodaq is primarily metabolized by
UGT1A1. Avoid concomitant administration of Beleodaq with strong
inhibitors of UGT1A1.
Use in Specific Populations
- It is not known whether Beleodaq is
excreted in human milk. Because of the potential for serious
adverse reactions in nursing infants from Beleodaq, a decision
should be made whether to discontinue nursing or discontinue drug,
taking into account the importance of the drug to the mother.
About MARQIBO®
MARQIBO is a novel, sphingomyelin/cholesterol
liposome-encapsulated, formulation of vincristine sulfate.
Vincristine, a microtubule inhibitor, is FDA-approved for the
treatment of adult patients with Philadelphia chromosome-negative
(Ph-) acute lymphoblastic leukemia (ALL) in second or greater
relapse or whose disease has progressed following two or more
anti-leukemia therapies. (The encapsulation technology, utilized in
this formulation, has been shown to provide prolonged circulation
of vincristine in the blood).
Please see important safety information below and the full
prescribing information for MARQIBO at
www.marqibo.com.
Indication and usage
MARQIBO is a liposomal vinca alkaloid indicated for the
treatment of adult patients with Philadelphia chromosome-negative
(Ph-) acute lymphoblastic leukemia (ALL) in second or greater
relapse or whose disease has progressed following two or more
anti-leukemia therapies. This indication is based on overall
response rate. Clinical benefit such as improvement in overall
survival has not been verified.
Important safety information
CONTRAINDICATIONS
- MARQIBO is contraindicated in patients
with demyelinating conditions including Charcot-Marie-Tooth
syndrome
- MARQIBO is contraindicated in patients
with hypersensitivity to vincristine sulfate or any of the other
components of MARQIBO (vinCRIStine sulfate LIPOSOME injection
- MARQIBO is contraindicated for
intrathecal administration
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to our business and its future, including
certain company milestones, Spectrum's ability to identify,
acquire, develop and commercialize a broad and diverse pipeline of
late-stage clinical and commercial products, leveraging the
expertise of partners and employees around the world to assist us
in the execution of our strategy, and any statements that relate to
the intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that our existing and new drug candidates may not prove safe or
effective, the possibility that our existing and new applications
to the FDA and other regulatory agencies may not receive approval
in a timely manner or at all, the possibility that our existing and
new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that
our efforts to acquire or in-license and develop additional drug
candidates may fail, our lack of sustained revenue history, our
limited marketing experience, our dependence on third parties for
clinical trials, manufacturing, distribution and quality control
and other risks that are described in further detail in the
Company's reports filed with the Securities and Exchange
Commission. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law.
SPECTRUM PHARMACEUTICALS, INC. ®, FUSILEV®,
FOLOTYN®, ZEVALIN®, MARQIBO®, and
BELEODAQ® are registered trademarks of Spectrum
Pharmaceuticals, Inc and its affiliates. REDEFINING CANCER CARE™
and the Spectrum Pharmaceuticals logos are trademarks owned by
Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2014 Spectrum Pharmaceuticals, Inc. All Rights Reserved
Spectrum PharmaceuticalsShiv KapoorVice President, Strategic
Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024